FDA grants fast track designation to lunresertib plus zedoresertib for genomic-defined platinum-resistant ovarian cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results